113 related articles for article (PubMed ID: 24831172)
1. Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study.
Bellevicine C; Bianco A; Malapelle U; De Luca C; Vigliar E; Cacciola NA; Pallante P; Troncone G
Cytopathology; 2015 Apr; 26(2):99-105. PubMed ID: 24831172
[TBL] [Abstract][Full Text] [Related]
2. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
4. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
Hasanovic A; Ang D; Moreira AL; Zakowski MF
Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
[TBL] [Abstract][Full Text] [Related]
6. Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality.
Dejmek A; Zendehrokh N; Tomaszewska M; Edsjö A
Cancer Cytopathol; 2013 Jul; 121(7):344-53. PubMed ID: 23408720
[TBL] [Abstract][Full Text] [Related]
7. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.
Xu H; Sun W; Zhang G; Cheng Y
J BUON; 2015; 20(1):142-5. PubMed ID: 25778309
[TBL] [Abstract][Full Text] [Related]
8. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ
Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821
[TBL] [Abstract][Full Text] [Related]
9. Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies.
Qu YG; Zhang Q; Pan Q; Zhao XD; Huang YH; Chen FC; Chen HL
Int J Nanomedicine; 2014; 9():5771-8. PubMed ID: 25525358
[TBL] [Abstract][Full Text] [Related]
10. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.
Yu J; Kane S; Wu J; Benedettini E; Li D; Reeves C; Innocenti G; Wetzel R; Crosby K; Becker A; Ferrante M; Cheung WC; Hong X; Chirieac LR; Sholl LM; Haack H; Smith BL; Polakiewicz RD; Tan Y; Gu TL; Loda M; Zhou X; Comb MJ
Clin Cancer Res; 2009 May; 15(9):3023-8. PubMed ID: 19366827
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
[TBL] [Abstract][Full Text] [Related]
13. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
Wang X; Wang G; Hao Y; Xu Y; Zhang L
Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
[TBL] [Abstract][Full Text] [Related]
14. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer.
Kitamura A; Hosoda W; Sasaki E; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2010 Jul; 16(13):3349-55. PubMed ID: 20570926
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR: a validation study.
Malapelle U; de Luca C; Vigliar E; Ambrosio F; Rocco D; Pisapia P; Bellevicine C; Troncone G
J Clin Pathol; 2016 May; 69(5):454-7. PubMed ID: 26893402
[TBL] [Abstract][Full Text] [Related]
17. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
Vora HH; Patel NA; Thakore PM; Shukla SN
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):653-60. PubMed ID: 25789532
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
[TBL] [Abstract][Full Text] [Related]
20. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
Simonetti S; Molina MA; Queralt C; de Aguirre I; Mayo C; Bertran-Alamillo J; Sanchez JJ; Gonzalez-Larriba JL; Jimenez U; Isla D; Moran T; Viteri S; Camps C; Garcia-Campelo R; Massuti B; Benlloch S; Ramon y Cajal S; Taron M; Rosell R
J Transl Med; 2010 Dec; 8():135. PubMed ID: 21167064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]